Checkpoint kinase 1 (CHK1)
CHEK1 encodes checkpoint kinase 1 (CHK1), a serine/threonine protein kinase that plays a central role in the cellular DNA damage response and replication checkpoint pathways.
CHEK1 encodes checkpoint kinase 1 (CHK1), a serine/threonine protein kinase that plays a central role in the cellular DNA damage response and replication checkpoint pathways. It helps coordinate cell-cycle arrest and DNA repair signaling, particularly under conditions of replication stress or genotoxic insult. By restraining cell-cycle progression when DNA integrity is compromised, CHK1 contributes to genome stability and cell survival.
In cancer biology, CHK1 is of interest as a therapeutic target because many tumor cells rely on checkpoint signaling to tolerate high levels of replication stress. Pharmacologic inhibition of CHK1 can disrupt this protective response, potentially pushing damaged or stressed cancer cells toward cell death. CHEK1 therefore has relevance both as a mechanistic node in DNA damage signaling and as a target in anticancer drug development.
Rebuilt from PubMed 5 Sept 2026 · no new papers today
Where the papers sit
8 papers study checkpoint kinase 1 (chk1) directly. The themes below are drawn from those 8.
-
Cancer Treatment Biomarkers : Prognostic risk models, hypoxia-linked radioresistance, and CHK1-targeted hesperidin liposomes point toward biomarker-guided cancer treatment. Manganese-metabolism signatures and tumor immune microenvironment features recur, but no single mechanism unifies the work. 3 papers · 37.5%
-
Replication Stress in Cancer : Replication-stress vulnerabilities are being exploited with WRN or Wee1/checkpoint inhibition, especially in ARID1A-mutant tumors, to force S-phase and mitotic failure. dNTP homeostasis and EGFR-mutant osimertinib resistance extend the focus toward genotype-guided combinations. 3 papers · 37.5%
-
Dual CHK1–AMPK Targeting : Prexasertib’s anticancer effect reflects dual CHK1–AMPK inhibition rather than CHK1 blockade alone. AMPKα Thr172 and mTOR signaling recur as determinants of tumor-cell death. 2 papers · 25%
Recent Findings on Checkpoint kinase 1 (CHK1)
Recent studies converge on CHK1 as a marker and mediator of treatment-relevant cell-cycle behavior across several cancer contexts, although the evidence ranges from prognostic association to therapeutic testing. In lung adenocarcinoma, CHEK1 was one of six manganese metabolism-related genes used to construct a survival-prediction model; its high expression was confirmed in tumors and cell lines, and the gene set was associated with cell-cycle regulation, immune-microenvironment features, and chemotherapeutic resistance 42472729Jul. In breast cancer, computational and experimental findings instead support direct pharmacologic targeting, with hesperidin-loaded liposomes showing CHK1 binding in silico, cytotoxicity in MCF-7 cells, antiangiogenic activity, and reduced tumor burden in a rat model 42166124May. In head and neck cancer, post-hypoxic cells acquired a mitotic survival advantage and radiotherapy resistance, while inhibition of ATR and CHK1/2 increased their radiosensitivity 41972846Apr. Thus, the studies differ in whether CHK1 is used primarily as a biomarker, a drug target, or a radiosensitization node, with the field moving toward context-specific strategies that combine CHK1 inhibition with chemotherapy or radiotherapy.
The two studies converge on prexasertib cytotoxicity arising from inhibition of both CHK1 and AMPK rather than from CHK1 blockade alone 42314651Jun42061410Apr. Prexasertib was reported to bind AMPK, initially increasing AMPKα Thr172 phosphorylation through CAMKK2 and LKB1 while also acting as an ATP-competitive AMPK inhibitor; prolonged exposure nevertheless suppressed AMPK activity, and AMPK depletion increased sensitivity to CHK1 inhibition 42061410Apr. The apparent discrepancy between AMPK phosphorylation and functional AMPK inhibition is therefore exposure- or mechanism-dependent rather than evidence of a uniform activating effect. These findings point toward exploiting kinase-inhibitor promiscuity and the AMPK/CHK1 interaction, with EXO1 hyperactivation proposed as a downstream mechanism of the resulting lethal DNA-replication stress 42314651Jun42061410Apr.
Recent work shows that CHK1- and CHEK2-dependent checkpoint responses determine whether stressed tumor cells arrest, re-enter the cell cycle, or undergo mitotic catastrophe, but the outcome is strongly dependent on genetic and treatment context. WRN inhibition in ARID1A-mutated cancers impaired CHK1-mediated DNA-damage signaling and induced compensatory CHEK2 activation, producing G1 arrest and apoptosis, whereas ARID1A-proficient cells underwent CHK1-dependent G2/M arrest; adding p21 inhibition forced cell-cycle re-entry and enhanced mitotic catastrophe in xenograft models 42247504Jun. In EGFR-mutant non-small-cell lung carcinoma, by contrast, CHK2 signaling supported TNNT3-dependent RRM2B induction to preserve dNTP pools during osimertinib-induced replication stress, and CHK2 or combined CHK1/2 inhibition impaired this adaptive response and delayed resistance 41941751Apr. The differing arrest patterns and checkpoint dependencies emphasize that CHK1 blockade is not uniformly cytotoxic across tumors, directing current strategies toward genotype- and treatment-specific combinations that disrupt DNA-damage adaptation or deliberately convert arrest into lethal mitotic failure.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-06-28. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.